Home » Stocks » Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. (TEVA)

Stock Price: $9.35 USD -0.09 (-0.95%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $9.33 -0.02 (-0.21%) Oct 23, 7:03 PM

Stock Price Chart

Key Info

Market Cap 10.25B
Revenue (ttm) 16.48B
Net Income (ttm) 4.00M
Shares Out 1.10B
EPS (ttm) 0.00
PE Ratio n/a
Forward PE 3.59
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $9.35
Previous Close $9.44
Change ($) -0.09
Change (%) -0.95%
Day's Open 9.45
Day's Range 9.32 - 9.49
Day's Volume 4,050,376
52-Week Range 6.25 - 13.76

More Stats

Market Cap 10.25B
Enterprise Value 34.52B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 1.10B
Float 1.10B
EPS (basic) 0.01
EPS (diluted) 0.00
FCF / Share 0.86
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 9.16%
Payout Ratio n/a
Shares Short 24.12M
Short Ratio 3.12
Short % of Float 2.20%
Beta 1.48
PE Ratio n/a
Forward PE 3.59
P/FCF Ratio 10.91
PS Ratio 0.62
PB Ratio 0.75
Revenue 16.48B
Operating Income 348.00M
Net Income 4.00M
Free Cash Flow 939.00M
Net Cash -24.28B
Net Cash / Share -22.15
Gross Margin 44.89%
Operating Margin 2.11%
Profit Margin n/a
FCF Margin 5.70%
ROA 3.31%
ROE -1.03%
ROIC 1.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (24)

Buy 4
Overweight 2
Hold 16
Underweight 1
Sell 1

Analyst Consensus: Overweight

Price Target

$12.14*
(29.84% upside)
Low
8.00
Current: $9.35
High
17.00
Target: 12.14
*Average 12-month price target from 19 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue16,88718,27121,85321,90319,65220,27220,31420,31718,31216,121
Revenue Growth-7.57%-16.39%-0.23%11.45%-3.06%-0.21%-0.01%10.95%13.59%-
Gross Profit7,5368,29610,61611,65311,35611,05610,70710,6529,5159,065
Operating Income-520-1,928-18,6821,3853,1863,9511,6492,2053,1093,871
Net Income-999-2,150-16,2653291,5883,0551,2691,9632,7593,331
Shares Outstanding1,0911,0211,016955855853849872890896
Earnings Per Share-0.91-2.35-16.260.071.823.561.492.253.093.67
EPS Growth----96.15%-48.88%138.93%-33.78%-27.18%-15.8%-
Dividend Per Share--0.721.361.261.161.090.810.790.67
Dividend Growth---46.91%8.11%8.17%6.7%34.57%2.53%17.91%-
Operating Cash Flow7482,4462,2253,8905,5425,1273,2374,5724,1344,136
Capital Expenditures-525-651-874-901-772-929-1,031-1,104-1,053-710
Free Cash Flow2231,7951,3512,9894,7704,1982,2063,4683,0813,426
Cash & Equivalents1,9751,7829639886,9462,2261,0382,8791,0961,248
Total Debt27,34228,91632,47535,8009,94310,32712,19114,71814,5166,881
Net Cash / Debt-25,367-27,134-31,512-34,812-2,997-8,101-11,153-11,839-13,420-5,633
Assets57,47060,68370,61593,05754,23346,42047,50850,60950,14238,152
Liabilities42,40744,88951,87058,06424,30623,06524,87227,74227,79916,150
Book Value13,97214,70717,35933,33729,76923,31322,56522,76822,19521,947
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Teva Pharmaceutical Industries Ltd.
Country Israel
Employees 40,039
CEO Kåre Schultz

Stock Information

Ticker Symbol TEVA
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: TEVA

Description

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.